10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-hnRNP L Picoband Antibody

Catalog # ABO10295

Product Information

Application	WB
Primary Accession	P14866
Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Format	Lyophilized
Description	Rabbit IgG polyclonal antibody for Heterogeneous nuclear ribonucleoprotein L (HNRNPL) detection. Tested with WB in Human.
Reconstitution	Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Additional Information

Gene ID	3191
Other Names	Heterogeneous nuclear ribonucleoprotein L, hnRNP L, HNRNPL, HNRPL
Calculated MW	64133
Application Details	Western blot, 0.1-0.5 □g/ml, Human
Subcellular Localization	Nucleus, nucleoplasm . Cytoplasm . Localized in cytoplasmic mRNP granules containing untranslated mRNAs. These granules are not identical with P bodies or stress granules. .
Source	Eukaryota
Protein Name	Heterogeneous nuclear ribonucleoprotein L
Contents	Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg NaN3.
Immunogen	A synthetic peptide corresponding to a sequence at the C-terminus of human HnRNP L (546-571aa LLEWESKSDALETLGFLNHYQMKNPN), different from the related mouse and rat sequences by one amino acid.
Purification	Immunogen affinity purified.
Storage	At -20˚C for one year. After r˚Constitution, at 4˚C for one month. It˚Can also be aliquotted and stored frozen at -20˚C for a longer time.Avoid repeated freezing and thawing.


Protein Information

Name	HNRNPL
Synonyms	HNRPL
Function	Splicing factor binding to exonic or intronic sites and acting as either an activator or repressor of exon inclusion. Exhibits a binding preference for CA-rich elements (PubMed:11809897, PubMed:22570490, PubMed:24164894, PubMed:25623890, PubMed:26051023). Component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes and associated with most nascent transcripts (PubMed:2687284). Associates, together with APEX1, to the negative calcium responsive element (nCaRE) B2 of the APEX2 promoter (PubMed:11809897). As part of a ribonucleoprotein complex composed at least of ZNF827, HNRNPK and the circular RNA circZNF827 that nucleates the complex on chromatin, may negatively regulate the transcription of genes involved in neuronal differentiation (PubMed:33174841). Regulates alternative splicing of a core group of genes involved in neuronal differentiation, likely by mediating H3K36me3-coupled transcription elongation and co-transcriptional RNA processing via interaction with CHD8.
Cellular Location	Nucleus, nucleoplasm. Cytoplasm. Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs. These granules are not identical with P bodies or stress granules

Background

Heterogeneous nuclear ribonucleoprotein L is a protein that in humans is encoded by the HNRNPL gene. Heterogeneous nuclear RNAs (hnRNAs) which include mRNA precursors and mature mRNAs are associated with specific proteins to form heterogenous ribonucleoprotein (hnRNP) complexes. HNRNPL is among the proteins that are stably associated with hnRNP complexes and along with other hnRNP proteins is likely to play a major role in the formation, packaging, processing, and function of mRNA. It is present in the nucleoplasm as part of the HNRP complex. HNRP proteins have also been identified outside of the nucleoplasm. Exchange of hnRNP for mRNA-binding proteins accompanies transport of mRNA from the nucleus to the cytoplasm. Since HNRP proteins have been shown to shuttle between the nucleus and the cytoplasm, it is possible that they also have cytoplasmic functions. Two transcript variants encoding different isoforms have been found for this gene.

Images



Western blot analysis of HnRNP L expression in PANC whole cell lysates (lane 1) and JURKAT whole cell lysates (lane 2). HnRNP L at 64KD was detected using rabbit anti-HnRNP L Antigen Affinity purified polyclonal antibody (Catalog # ABO10295) at 0.5 □¼g/mL. The blot was developed using chemiluminescence (ECL) method .

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.